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A L I G N A N T G L I O M A S ,
with disproportionately high morbidity and mortality, 1 are among the most devastating of human tumors. Particular genomic alterations are fundamental to both their formation and their malignant progression. 2 , 3 Although genomic instability (BOX) lends a dynamic character to the human glioma genome, gliomas harbor recurrent chromosomal alterations (Box). 2, 4, 5 Chromosomal alterations presumably exert their tumor-promoting effect on glioma cells by modifying the expression or function of distinct genes, which map to those alterations, 6 so as to deregulate growth factor signaling and survival pathways. For many chromosomal alterations, the biologically relevant target genes remain to be discovered.
Oncogenic research on gliomas has focused on the tumor-promoting or tumor-suppressive function of target genes within individual chromosomal alterations. 7 However, these alterations do not exist in isolation, nor do single genes account for gliomagen-esis. Rather, there may be mechanistic links to genes at other, coincident alterations. To the extent that a set of coincident alterations confers a survival advantage, cells possessing it will be selected by somatic evolution.
A major challenge in cancer research is to distinguish genetic changes that directly drive the disease process from "passenger" mutations, which are neutral to the process and have been accumulated by chance. 8 Herein, we take a systems biology approach to this complexity by integrating multidimensional genomic data and functional interactions among genes. The goal is to reduce the complexity and dimensionality of these data to provide biological insights that may translate into improved management of high-grade gliomas. Our central hypothesis is that such an approach reveals a nonrandom genetic landscape (Box)-a consistent pattern of distinct chromosomal alterations-in gliomas, which facilitates gliomagenesis in a cooperative fashion. Using more than 500 glioma samplesincluding multidimensional data from The Cancer Genome Atlas Pilot Project (TCGA), which aims to discover major cancer-causing genome alterations-we delineate the relationships of tumor-promoting genes in gliomas. At the molecular level, these relationships explain the selection of such a complex genetic landscape during gliomagenesis, and at the clinical level, they impart prognostic insight and suggest therapeutic strategy.
METHODS
Tumor Samples
Forty-five fresh-frozen glioma specimens of varying morphology were collected at Stanford University under Stanford Institutional Review Boardapproved guidelines. Written informed consent was obtained from all patients. Specimens were analyzed by a neuropathologist to confirm the histological diagnosis and the presence of vital tumor tissue without excessive contamination (Ͻ10%) by normal brain and tumor necrosis. Genome-wide gene dosage (Box)-the copy number for a specific gene-data were generated as previously reported 4 using sex-matched reference DNA (Promega, Madison, Wisconsin) and a Stanford human complementary DNA (cDNA) microarray containing 41 421 Integrated Molecular Analysis of Genomes and Their Expression (IMAGE) Consortium cDNA clone objects 9 (hereafter referred to as clones) corresponding to 27 290 different UniGene cluster IDs (Stanford Functional Genomics Facility, Stanford, California). Corresponding genome-wide expression profiles for these tumors and pooled normal human brain RNA (Stratagene, La Jolla, California) were previously reported. 10, 11 Raw data for gene dosage and expression profiling are available at Gene Expression Omnibus (http: //www.ncbi.nlm.nih.gov/geo/) with accession numbers GSE1991 and GSE2223, respectively, and at the Stanford Microarray Database (SMD) (http: //smd.stanford.edu/). Agilent Human Genome CGH Microarray 244A gene dosage data, Affymetrix HT Human Genome U133A Array Plate Set gene expression data, and clinical data for 219, 188, and 207 glioblastomas, respectively, were obtained from the OpenAccess and Controlled-Access Data Tiers Portal (http://tcga-data.nci.nih
Box. Glossary a
Chromosomal alteration is an irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.
Chromosomal rearrangement encompasses several different classes of events: deletions, duplications, inversions, insertions, and translocations. Each of these events can be caused by breakage of DNA double helices in the genome at 2 different locations, followed by a rejoining of the broken ends to produce a new chromosomal arrangement of genes, different from the gene order of the chromosomes before they were broken. Insertions and translocations can involve the exchange of genetic material between nonhomologous chromosomes.
Cytogenetic bands correspond to an alternating dark and light banding pattern of chemically stained chromosomes and provide a tool by which abnormalities in chromosomes from diseased cells can be identified.
Gene dosage refers to the copy number for a specific gene determined in analytic approaches that do not assess single cells but describe the average copy number profile of a complex tumor in which some cell populations may harbor copy number alterations of a distinct gene and some may not.
Genome-wide gene dosage profile is a gene-by-gene representation of gene copy numbers across the whole genome displayed in genome order along the chromosomes.
Genomic instability is a biological process consisting of chromosomal rearrangements and duplications. These phenotypes are often seen in the karyotype of cancer cells, where there is an imbalance between the mechanisms of cell-cycle control and mutation rates within aberrant genes.
Interactome is the whole set of molecular interactions in cells, most notably protein-protein interactions and protein-DNA interactions.
Landscape gene is a gene mapping to a chromosomal region that is part of a consistent pattern of chromosomal alterations.
Nonrandom genetic landscape is a consistent pattern of distinct chromosomal alterations. Nonrandomness refers to the significant co-occurrence of these alterations and not to their recurrence frequency. A random alteration may well recur in gliomas and, thus, represent a biological consistency, but there is no statistically recognizable pattern of its recurrence with other alterations. 15 from the R package "DNAcopy" (http://www.r-project.org/) was used to estimate segmented regions of equal dosage along each chromosome using 33 245 clones that passed initial data normalization and filtering. To increase the number of estimated segmented regions obtained by CBS and thereby the sensitivity of the algorithm, the ␣ level was set to .05 rather than the default of .01. Segmented gene dosage values were deemed changed compared with normal human reference DNA if they fell outside of the ±3-SD range of all segmented log 2 values of control (glioma and normal brain) self-to-self hybridizations, resulting in classification as copy number "gain" for gene dosage values Ͼ0.2135 and "loss" for gene dosage values Ͻ−0.2135. Agilent Human Genome CGH Microarray 244A data from TCGA were background corrected using subtraction then replacement of negative or zero values with half the minimum of the positive corrected values on the array, then were LOWESS normalized using the "limma" package for R. Data from TCGA were similarly processed as described above using CBS via the "snapCGH package" for R. Gene dosage segments were classified as chromosomal gain or loss if the absolute value of the predicted dosage was more than 0.75 times the interquartile range of the difference between observed and predicted values for each region. Gene expression data deposited into the SMD were background subtracted and included for downstream analysis if the reference channel intensity was at least 1.5 times the observed background. LOWESS normalization was performed using SNOMAD and TIGR MIDAS. Preprocessed gene expression data obtained from TCGA, 2 MDA, 12 UCLA, 13 and Lee et al 14 were normalized as previously described.
Gene Dosage Data Analysis
We developed a new permutationbased approach, which calculates the probabilistic fit for the coincidence of distinct chromosomal alterations. Geneby-gene CBS dosage data were averaged for each of 802 chromosomal cytogenetic bands (Box) corresponding to standard chromosomal high-resolution banding, based on an International System for Human Cytogenetic Nomenclature (ISCN) 850 chromosome ideogram. 16 For each tumor (t) and cytoband (i), measurements x [t,i] were scored ϩ1 for gain, −1 for loss, and 0 otherwise (ie, unchanged). Scores were mapped into a data matrix (x) with tumors and cytobands ordered as rows and columns, respectively. The association of alterations within each possible combination of 2 cytobands (i, j) was assessed based on computing the score S [i,j] 
Gene Dosage and Expression Integration
For the Stanford samples, gene dosage and gene expression data (expression in Ͼ80% of tumors) were available for 15 608 clones that mapped to 10 351 genes, 7509 of which had either losses or gains in at least 2 tumors. For the latter, signal-to-noise (s2n) ratios were computed to assess the influence of dosage alteration for each gene on its transcript, [17] [18] [19] defined by the difference of the means (m) of expression levels in the groups of gene dosage-altered (m c ) and -unaltered (m n ) samples, divided by the sum of standard deviations (s) of expression levels in both groups (s c and s n , respectively). The above data matrix x was transformed such that gene dosage change (c) was assigned g for gain, l for loss, and n otherwise. The significance of the s2n ratio for each gene was estimated by randomly permuting the gene alteration labeling vector 10 000 times. We further determined corresponding FDR-adjusted
, q values using the "qvalue" package for R (default parameters), 20 allowing for a more straightforward interpretation of statistical significance in the context of multiple hypothesis testing. False-discovery rate estimation was performed by setting fixed cutoffs and estimating the FDR by permutations as previously described. 20 These computations were done separately for l vs n and g vs n. For clones with alterations in both directions, s2n ratio and corresponding q value for the more recurrent change were chosen. Similar s2n calculations and permutation-based P value computations were conducted to test and validate associations between gene dosage and gene expression for selected candidate genes using TCGA gene dosage and expression data. Due to the intentional selection of these genes for hypothesis testing in TCGA data, FDR was controlled using the method of Benjamini and Hochberg, 21 a limiting case of q value correction.
Gene Set Enrichment Analyses and Modeling of Gene Interactions
Gene set enrichment analyses, using hypergeometric testing for the set of genes with significant gene dosagegene expression relationships, were executed using Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Mountain View, California) to identify overrepresented biological functions and signaling pathways from the IPA database for this gene set with righttailed P Ͻ .05. Ingenuity Pathways Analysis was also used to identify direct and indirect physical (proteinprotein) and functional interactions between genes with significant gene dosage-gene expression relationships. An initial gene set was first overlaid onto the set of all cataloged IPA interactions and "focus genes" required in the IPA algorithm were identified as the subset having direct interactions with other genes in the initial set. The specificity of a gene's interactions was calculated as the percentage of its interactions with other significant genes in the initial set. Genes with the highest specificity of connections were used for the initiation and growth of biological networks with a maximum of 35 genes. Networks of highly interconnected genes were identified by statistical likelihood as follows:
where N is the number of genes in the genomic network, of which G are focus genes, for a network of s genes, f of which are focus genes; and C(N,s) is the binomial coefficient. The score reflects the negative logarithm of the P value that signifies the likelihood of the focus genes in a network being found together as a result of random chance. We merged the top-scoring networks using a "force-direct layout algorithm" to form a composite network representing the underlying biology of the process. Gene set enrichment analyses for the composite network were computed as above. For purposes of further investigation, genes with connectivity (ie, number of interactions with other genes) above the 95% quantile of the overall distribution of gene connectivity in the composite network were deemed network "hub" genes. Genes with tumor-related biological functions and interactions with hub genes were deemed "hub-interacting" genes. For the interaction of the hub genes with each other and with the hubinteracting genes, the mode of functional interaction was integrated with the direction of gene dosage change of each gene constituent of a gene pair to determine the presence of a cooperatively tumorigenic relationship. The BioGRID protein interaction repository 22 was used to confirm high connectivity of candidate genes yielded by the IPA analyses by providing an experimentally based data source for physical protein interactions. The entire set of interactions observed in humans (release 2.0.51; March 26, 2009 ) was downloaded and the number of interactions (or connectivity) observed for all proteins represented in the data set was compared with the number of interactions observed for the candidate genes yielded by the IPA analyses using a Wilcoxon rank-sum test.
Survival Analysis and Multigene Predictor
Survival curves were estimated by the Kaplan-Meier product-limit method, and survival distributions between groups were compared using the logrank test. Univariate and multivariate Cox proportional hazards regression analyses were performed with overall survival as the dependent variable, and the proportional hazards assumption was tested using interactions with time.
To create a multigene predictor model, we first selected predictor genes based on their statistical significance at PϽ.05 in univariate Cox models relating continuous gene dosage data to survival in the TCGA data set. To combine data for the 7 detected genes, we used a schema according to the presence of alterations of these genes in individual tumors. Based on the number of alterations we assigned tumors to a highrisk group (Ն5 of 7 genes altered in the direction associated with gliomagenesis) and a low-risk group (Յ2 genes altered). The remainder of the tumors were considered moderate-risk. For the data sets that only included gene expression data without gene dosage data, we used transcript levels above or below their respective medians within a data set to reflect possible chromosomal gain or loss. For genes whose deletion or amplification demonstrated association with survival data at the genetic level in the TCGA analysis, we assigned an "alteration call" to denote potential chromosomal loss or gain if the transcript level was below or above the median. We created low-, moderate-, and high-risk groups for the transcript data based on the number of alteration calls using the same criteria as for the genetic data.
Statistical Calculations and Data Visualization
Unless otherwise specified, all statistical calculations were performed using R software, version 2.8.1, and pack- (Figure 1) , and their boundaries throughout the glioma genome (eFigure 1, available at http://www .jama.com). We modeled the association of chromosomal alterations with each other. FIGURE 2A shows a genome-wide association matrix for 802 chromosomal cytogenetic bands (cytobands; Box)-subregions of a chromosome visible microscopically after special staining-in the 45 Stanford tumors. Numerous significant (FDRϽ0.05) cytoband-cytoband associations are identified across the human glioma genome (Figure 2A ). Filtering of those associations for more than 10% frequency identifies an initial genetic landscape of aneuploidy (-, losses; ϩ, gains) involving 10 networking regions (or territories) on chromosomes 1p−, 7ϩ, 8qϩ, 9p−, 10−, 12qϩ, 13q−, 19q−, 20ϩ, and 22q− displaying 37 associations ( Figure 2B ). An independent validation analysis of 219 TCGA glioblastomas using the same permutation-based approach reveals a very similar association matrix (FIGURE 3A), confirming 9 (90%) of 10 chromosomal territories (except for the long arm of chromosome 1p) and 21 (56.8%) of 37 territorial associations ( Figure 3B ). The chromosomal territories confirmed in this validation analysis are hereafter referred to as a (TCGA-validated) genetic landscape.
Gene Dosage Reflected in Gene Expression
We observed a significant (qϽ. 10 We noted a widespread association of changes in gene dosage and expression across the glioma genome (eFigure 3). However, there was a greater likelihood for a gene dosage effect on the expression of genes mapping to the genetic landscape than on the expression of genes mapping to random genetic alterations (PϽ.001 by Pearson 2 test; odds ratio, 7.7; 95% CI, 6.9-8.6) (eFigures 3 and 4). Within the genetic landscape, we noted a greater propensity for alterations to be hypomorphic, ie, to reduce gene expression, rather than hypermorphic, ie, to increase gene expression (for hypomorphic vs hypermorphic, odds ratio, 8.4; 95% CI, 7.3-9.6 vs 3.5; 95% CI, 2.8-4.2; P Ͻ .001 for both) (eFigures 3 and 4).
Highly Interacting Landscape Genes
Genes with a role in gliomagenesis are more likely to function as part of a cooperative group or network rather than individual units. 10, 27, 28 Our hypothesis that the characterized common genetic landscape alters biological networks to promote glioma formation prompted network modeling to identify the interaction of the genes affected by dosage effects in the glioma genome. This yielded a "node-andedge" graph that maps 214 genes (represented as nodes) into a network of various physical (protein-protein) or functional interactions (represented as edges connecting the nodes) (FIGURE 4) . The modeled interactions are both directed (well-defined information flow; eg, from a transcription factor to the gene it regulates) and undirected (eg, mutual binding relationships). Gene set enrichment analyses revealed a greater probability for overrepresentation of tumor-promoting (83.1% of genes) and developmental (29.5%) functions and pathways in the network than for all 1562 gene dosagedriven genes (eFigure 2).
The organization of genes and proteins into functional networks likely reflects cellular function. 27 We studied the genes with high connectivity (a large number of incident edges), as their alteration may affect many other genes in the network; such highly influential genes should be preferred therapeutic targets. We identified 11 highly connected hub genes ( Figure 4 and eFigure 5A), all of which have a tumor-promoting function and notably included genes with a known biological role in gliomagenesis, such as EGFR, MYC, PTEN, and BAX. Genes that interact functionally with the hub genes are also likely to fundamentally influence the network. Analysis of the reciprocal functional relationship of the 11 hub genes with each other and with 92 hub-interacting genes with a tumor-related function disclosed 125 cooperatively tumorigenic gene-gene relationships (Figure 4) . A matched-pair analysis of the number of putatively cooperative vs noncooperative interactions for those genes revealed a significant prevalence (125 [71.8%] of all 174 interactions; P = .003 by paired t test) of cooperatively tumorigenic relationships in the network (eFigure 6).
We found that 6 (54.5%) of 11 hub genes and 52 (56.5%) of 92 
Gene dosage Loss
Cartesian line diagrams depict the frequency of gene dosage alteration across a tumor population for genes mapped according to genome position along the chromosomes (X and Y chromosomes omitted). Gene dosage profiles were generated using circular binary segmentation change point analysis of microarray-based genomic hybridization profiles. Both the discovery and validation sets show consistently high frequencies of alterations involving chromosomes 1p, 7, 8q, 9p, 10, 12, 13, 19, 20, and 22. IMAGE indicates Integrated Molecular Analysis of Genomes and Their Expression Consortium.
tumor-related hub-interacting genes mapped to the TCGA-validated genetic landscape. We tested the nonrandomness of coalteration of the individual hub and hub-interacting genes mapping to the genetic landscape (the landscape hub and hubinteracting landscape genes, constituting together the landscape genes) by applying the same approach used initially to model a genome-wide genetic landscape. We then integrated the association data with the interaction data of our network model ( Figure 4) 
broadly dispersed throughout the T C G A -v a l i d a t e d l a n d s c a p e ( Figure 5 ).
To validate a significant genetranscript correlation for the 31 landscape genes with cooperatively tumorigenic relationships, we integrated corresponding gene dosage and expression profiles in TCGA using a statistical approach similar to that above. Combined gene dosage and gene expression data were available for 30 of the 31 genes in TCGA's data set. This analysis confirmed significant gene dosage effects on expression for 27 (90.0%) of the 30 genes, excluding MGAT3, MYBL2, and PCNA (Benjamini- A permutation-based approach, which calculates the probabilistic fit for the coincidence of distinct chromosomal alterations, was applied to the gene dosage data in the discovery set from Stanford University. The gene dosage data generated by the circular binary segmentation change point algorithm were averaged according to 802 cytogenetic bands (cytobands)-subregions of a chromosome visible microscopically after special staining-that correspond to an International System for Human Cytogenetic Nomenclature (ISCN) 850 chromosome ideogram. The association map (A) indicates chromosomal regions (territories) with significant co-occurrence of gene dosage alteration (false-discovery rate [FDR]-corrected PϽ.05). Red scores denote the significant association of 2 chromosomal gains or 2 chromosomal losses; blue scores, the significant association of a gain and a loss event. The color gradation reflects a score that indicates the significance of cytoband-cytoband associations. The association map shows a consistent pattern of significant associations, which denotes a nonrandom genetic landscape in gliomas. B, Chromosomal territories that showed an alteration frequency of greater than 10% (involving chromosomes 1p, 7, 8q, 9p, 10, 12, 13, 19, 20, and 22) in the discovery set and their significant associations are mapped to a human ISCN-850 chromosome ideogram. (See interactive Figure 1 showing significant associations in the discovery and validation sets at http://www.jama.com.)
Hochberg FDR-corrected PϽ.05) ( Figure 5 ).
Finally, we confirmed high connectivity for 25 of the 27 validated landscape genes (MFN2 and ABCC4 did not have interactions reported at the time of analysis) using BioGRID, a general repository for protein-protein interactions. For 8445 available genes (the entire set of human protein interactions) with at least 1 interaction reported in humans, there were 30 386 gene-gene pairs with at least 1 reported interaction between them. The median number of reported interactions for the entire data set was 3 (range, 6, A and B) . Supervised group predictor analysis revealed highest group-predictive power for altered genes on chromosomes 7 and 10.
We hypothesized that the group of tumors with extensive landscape gene alterations might be those that are biologically more aggressive and, hence, have a worse prognosis. A 2-class model confirmed a significant difference in Permutation-based approach described in Figure 2 was applied to the validation set from The Cancer Genome Atlas Pilot Project (TCGA). The association map (A) indicates chromosomal regions (territories) with significant co-occurrence of gene dosage alteration (false-discovery rate [FDR]-corrected PϽ.05). Red scores denote the significant association of 2 chromosomal gains or 2 chromosomal losses; blue scores, the significant association of a gain and a loss event. The color gradation reflects a score that indicates the significance of cytoband-cytoband associations. The association map shows a consistent pattern of significant associations, which denotes a nonrandom genetic landscape in gliomas. B, Significant associations identified in the discovery set ( Figure 2B ) that were confirmed in the TCGA validation set. The blue bars and corresponding blue labels indicate chromosome territories with TCGA-confirmed significant associations to other territories (TCGA-validated nonrandom genetic landscape). (See interactive Figure 1 showing significant associations in the discovery and validation sets at http://www.jama.com.) 
Node Shapes
Graphical representation of the interactions and networking of 214 glioma genes. The 214 genes represent the subset of all 1562 genes with significant gene dosage-transcript relationships (false-discovery rate-adjusted qϽ.10) that map to the top-scoring subnetworks identified in a network modeling approach using Ingenuity Pathway Analysis. These subnetworks were merged using a force-directed layout algorithm to form a composite network representing the underlying biology of the process. Genes are represented as nodes using various shapes that represent the functional class of the gene product. The interactions of genes with tumor-related biological functions and fulfilling the criterion of a network hub (11 genes) or interacting with hub genes (hub-interacting gene; 92 genes) are highlighted. Hub gene refers to a gene that shows a number of interactions with other genes (the hub-interacting genes or other hub genes) that is above the 95% quantile of the overall distribution of the number of interactions of all genes in the network (eFigure 5A). 
RANGAP1
Human chromosome ideogram representation of the networking of 31 hub and hub-interacting genes that map to The Cancer Genome Atlas Pilot Project (TCGA)-validated genetic landscape and possess cooperatively tumorigenic relationships. These cooperatively tumorigenic relationships emerge through the mode of interaction between the genes and their significant coalteration. Gene dosage-gene expression integration for 30 of the 31 genes with combined availability of gene dosage and expression data in TCGA confirmed significant gene dosage effects on transcription for 27 (90.0%) of 30 genes (Benjamini-Hochberg false-discovery ratecorrected PϽ.05). Labels indicate the cytogenetic band mapping of the genes. a Genes with a significant (P Ͻ .05) relationship between gene dosage and duration of patient survival in the TCGA data set based on Cox proportional hazards regression analysis. b Genes without confirmed significant gene dosage-gene expression relationship in the TCGA data set. c TIMP3 is embedded within an intron of the SYN3 gene. Gene dosage information for TIMP3 was only indirectly available through a probe mapping to SYN3 in TCGA. Integration of gene dosage information using this probe and TIMP3 transcript information revealed a significant (PϽ.05) gene dosage-transcript relationship. spread landscape gene alterations had a 2-year survival rate of 12.9% and 82.34 deaths per 100 person-years vs a 2-year survival rate of 32.0% and 48.31 deaths per 100 person-years for tumors with modest alterations.
Multigene Predictor Model
To determine the potential utility of a concise molecular profile in estimat- ing the prognosis of an individual glioblastoma patient, we assessed the survival association of gene dosage for each of the 27 validated landscape genes in TCGA glioblastomas. Cox proportional hazard regression indicated statistically significant survival associations for 7 landscape genes, including the DNA polymerase delta 2, small subunit (POLD2) (P = .01) and cytochrome C, somatic (CYCS) (P = .01) genes on chromosome 7, the MYC oncogene on chromosome 8 (P=.03), and the aldo-keto reductase family 1, member C3 (AKR1C3) (P = .002), YME1-like 1 (YME1L1) (P=.006), annexin A7 (ANXA7) (P=.008), and programmed cell death 4 (neoplastic transformation inhibitor) (PDCD4) (P=.01) genes on chromosome 10. Each of the 7 genes has a biological function whose alteration might contribute to tumorigenesis. The avian myelocytomatosis homologue (MYC) is a major oncogene 10 ; ANXA7 is a candidate tumor suppressor gene in breast and prostate cancer [29] [30] [31] [32] [33] and its protein product is a phosphorylation target of the epidermal growth factor receptor (EGFR) oncoprotein 34 ; AKR1C3 and PDCD4 have been implicated in colorectal cancer 35, 36 and their expression is regulated by phosphatase and tensin homolog (PTEN) 37 ; YME1L1 has been related to cancer development and progression 38 and has been identified as an MYC-responsive gene, 39 as has CYCS. 40 The protein encoded by POLD2 is a subunit of the DNA polymerase delta complex, which also contains the protein product of the landscape gene PCNA; it is involved in DNA replication and repair and its expression is regulated by PTEN. 37 In the TCGA training set of 189 glioblastomas, the combined 7-gene predictor model assigned 119 tumors to a high-risk group (Ն5 of 7 genes altered) with a median duration of follow-up of 49.3 (range, 2.4-307.4) weeks, 39 to a low-risk group (Յ2 genes altered) with a median follow-up of 62.9 (range, 10.6-503.4) weeks, and 31 to a moderate-risk group (all others) with a median follow-up of 51.0 (range, 1. 7A) . Similar multigene models using gene expression data revealed significant differences in survival for the MDA and UCLA validation sets (Figure 7 , B and C). In the MDA set, 23, 33, and 20 patients were assigned to the low-, moderate-, and high-risk groups and had median follow-up times of 175 (range, 33- Figure 7B ). In the UCLA set, 20, 34, and 16 patients were assigned to the low-, moderate-, and high-risk groups and had median follow-up times of 128.5 (range, 6-359) weeks, 58.5 (range, 8-320) weeks, and 49 (range, 1-147) weeks, respectively. The low-, moderate-, and high-risk groups demonstrated 16.14, 38.41, and 83.43 deaths per 100 person-years, respectively. A log-rank test for all 3 curves yielded P = .008 and Cox modeling yielded an HR of 3.86 (95% CI, 1.59-9.35; P =.003) comparing high-risk vs low-risk groups and an HR of 2.12 (95% CI, 0.97-4.63; P=.06) comparing moderate-risk vs low-risk groups, respectively ( Figure 7C ). In the multiinstitutional validation set of 191 glioblastomas, 43, 92, and 56 patients were assigned to the low-, moderate-, and high-risk groups and had median follow-up times of 73 (range, 1-479), 57.5 (range, , and 47 (range, 1-242) weeks, respectively. The low-, moderate-, and high-risk groups demonstrated 34.16, 63.49, and 83.23 deaths per 100 person-years, respectively. A log-rank test for all 3 curves yielded P = .002 and Cox modeling yielded an HR of 2.27 (95% CI, 1.44-3.58; PϽ.001) comparing high-risk vs low-risk groups and an HR of 1.72 (95% CI, 1.14-2.59; P = .01) comparing moderate-risk vs low-risk groups ( Figure 7D ), confirming the robustness of the multigene predictor model in glioblastoma at the expression level. Although gene dosage was prognostic in TCGA tumors, we did not find an association between mRNA expression and survival in the TCGA data set. Heterogeneity of patient characteristics and treatment (tumor samples collected over nearly 2 decades at varying institutions) and the fact that gene transcription is more dynamic and fluctuant than gene dosage may explain the disparity in findings in the TCGA group at the genetic and transcript levels.
COMMENT
The pathobiology of human gliomas emerges through the actions of multiple genes and their interactions with each other. As the classic theories regarding glioma origin and gliomagenesis are currently being reappraised, 41 we used a systems biology approach without regard to morphological subtypes to generate a model of a nonrandom genetic landscape in gliomas. Herein, nonrandomness describes a significant association of distinct chromosomal alterations. Our model proposes that this genetic landscape involves multiple reciprocal gene alterations, which cooperatively promote gliomagenesis and contribute to unfavorable patient prognosis, thus providing the selection pressure for its conservation.
Identification of the importance and mechanistic interplay of such gene alterations in gliomas prompts evaluation of their potential as therapeutic targets. The network context of a gene likely affects the efficacy of therapies that target its protein. 42 This paradox is resolved by the fact that the deregulation of EGFR in glioblastomas does not exist in isolation. But rather, the functional organization of EGFR, and other gene dosage-altered genes within the landscape, in a complex network of interactions predicts that monotherapeutic approaches will fail: extensive cross-talk between interacting genes and their pathways permits resistance to therapy. The topology of our landscape model suggests that molecular targeting of multiple (hub) genes will be more effective.
Our study has limitations. First, our landscape model reduces the biological complexity of human gliomas to the genetic level. However, the fundamental mechanisms of carcinogenesis include both genetic and epigenetic events. Future integration of genetics and epigenetics could better explain gliomagenesis. Second, our model assumes that cancer cells modify only preexisting biological pathways. But, in complex diseases such as gliomas, genes may additionally interact in new pathways and networks. Therefore, exploration of gene networks without a priori assumptions may complement this network approach based on known gene interactions. We recognize that the connectivity (and, thus, the potential importance) of genes in a network like ours depends not only on biological reality but also on sampling, experimental conditions, and reporting of results; there may be other genes that significantly contribute to network behavior that our model has not addressed. Furthermore, the candidate gene-gene interactions that emerged from our model need to be further tested mechanistically in a brain tumorspecific context. And, finally, our assumption of nonrandom coselection of distinct chromosomal alterations may be invalidated by chromosomal rearrangement (Box) of parts between nonhomologous chromosomes in the genetic landscape. Recent evidence suggests that recurrent translocations might be more common in solid tumors than previously appreciated. 43 However, physical rearrangements have not been reported for the chromosomal territories mapping to our TCGA-validated genetic landscape in gliomas, nor could they explain the frequent coselection of chromosomal loss and gain events within the landscape.
To date, therapeutic decisions for human gliomas are mainly guided by inexact and heterogeneous clinical and morphological measures. Risk estimation in glioblastomas, which share similar pathological characteristics but show substantial variation in outcome, is particularly challenging. This calls for better risk estimation strategies, which might improve treatment efficacy and quality of life. Such strategies have to take into account the key mechanisms contributing to glioblastoma pathogenesis.
Several gene sets have been proposed as multigene predictors of glioblastoma patient survival. 5, 13, [44] [45] [46] Many of those sets have used so-called metagenes-patterns of gene expressionfor risk classification. Although metagenes support the notion that, in a complex glioblastoma tumor, it is not a single gene but, rather, multiple genes that drive the disease process, the risk associations of metagenes are primarily correlative. While metagenes, by definition, constitute gene subsets identified without considering underlying mechanisms, some studies have shown that such metagenes can characterize clinically relevant molecular subtypes of high-grade gliomas. [12] [13] [14] Recently, a consensus gene expression profile associated with patient outcome across independent data sets and an optimized 9-gene metagene predictor have been reported for high-grade gliomas. 47 While the primary role of multigene predictor models would be to prospectively identify glioma patients with low vs high likelihood for a durable response to standard therapy, molecular predictor models that place genes into pathways and networks allow mechanistic insights that are crucial for developing novel molecularly targeted therapies. We show that a focused set of 7 landscape genes associates with patient survival across several different study populations with discrimination similar to that of correlative multigene predictors. These observations lay the foundation for future development of a mechanistically based molecular risk estimation model in glioblastomas and high-grade gliomas. In our study, the multigene predictor model associates with survival when taking into account either genetic or transcriptional information about those genes. The genetic model might lend itself better to translation into clinical practice for 2 reasons. First, while the expression of an individual gene can vary over short periods of time in cancers, gene dosage is more static and more amenable to predictive screens. Second, the gene expression model depends on risk groupings in which the transcript profile of an individual patient is related to the profiles of other patients, with a potential for demographic bias. In contrast, the genetic predictor allows risk estimation based on a patient's individual biological profile by using a binary model (the gene is altered or it is not).
CONCLUSION
The current work provides a network model and biological rationale for the selection of a nonrandom genetic landscape in human gliomas. Coincident genetic alterations of multiple landscape genes may evolve rapidly under positive selection to provide multiple, synergistic mechanisms of dysregulation of critical signaling pathways toward gliomagenesis. A multigene predictor model incorporating 7 landscape genes demonstrates how molecular insights emerging from our integrative multidimensional analysis could translate into relevant clinical end points affecting the future management of gliomas.
